Trials / Recruiting
RecruitingNCT07153471
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee
A Phase 3 Study to Investigate the Efficacy and Safety of Orforglipron Once Daily in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee: A Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Trial
- Status
- Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 800 (estimated)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The GZPT master protocol will support two independent studies, J2A-MC-GZT1 and J2A-MC-GZT2. Each study will see how well and safely orforglipron works in people with obesity or overweight who have osteoarthritis (OA) of the knee with pain. Participation in the study will last about 74 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Orforglipron | Administered orally |
| DRUG | Placebo | Administered orally |
Timeline
- Start date
- 2025-09-15
- Primary completion
- 2028-04-01
- Completion
- 2028-05-01
- First posted
- 2025-09-04
- Last updated
- 2026-04-17
Locations
95 sites across 8 countries: United States, Canada, China, Germany, India, Japan, Mexico, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07153471. Inclusion in this directory is not an endorsement.